DKK 411.6
(6.85%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 60.68 Million DKK | -0.45% |
2022 | 60.96 Million DKK | 32.81% |
2021 | 45.9 Million DKK | -11.19% |
2020 | 51.68 Million DKK | 2.72% |
2019 | 50.31 Million DKK | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | - DKK | 0.0% |
2024 Q2 | - DKK | 0.0% |
2023 FY | 60.68 Million DKK | -0.45% |
2023 Q3 | 60.68 Million DKK | -8.83% |
2023 Q2 | 66.56 Million DKK | 0.0% |
2023 Q4 | 60.68 Million DKK | 0.0% |
2023 Q1 | 66.56 Million DKK | 9.19% |
2022 Q4 | 60.96 Million DKK | 0.0% |
2022 FY | 60.96 Million DKK | 32.81% |
2022 Q3 | 60.96 Million DKK | 0.0% |
2022 Q1 | - DKK | 0.0% |
2021 FY | 45.9 Million DKK | -11.19% |
2020 FY | 51.68 Million DKK | 2.72% |
2019 FY | 50.31 Million DKK | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
ALK-Abelló A/S | 439 Million DKK | 86.177% |
Bavarian Nordic A/S | 15.13 Million DKK | -300.958% |
Genmab A/S | 680 Million DKK | 91.076% |
Novo Nordisk A/S | 20.52 Billion DKK | 99.704% |
Orphazyme A/S | - DKK | -Infinity% |
Pharma Equity Group A/S | 8.07 Million DKK | -651.796% |
Zealand Pharma A/S | 102.57 Million DKK | 40.838% |